17th June 2021

Successful First In-Human use For Creo Device

Creo Medical Group has hailed the first in-human use of US Food & Drug Administration-cleared device which was successful in adding months to a patient’s life expectancy and well-being.

The Chepstow-headquartered business’ MicroBlate Fine product was used in endoscopic ultrasound (EUS) guided, treatment in a patient with an unresectable pancreatic neuroendocrine tumour.

Following the procedure, the patient was said to remain well and is enjoying life.  Subsequent scans of the patient’s pancreas continue to confirm the treatment’s durability.

The procedure was performed by Dr Carlos Robles-Medranda at Instituto Ecuatoriano de Enferemdades Digestives, in Ecuador, who said: “I am excited about the potential of this technology for use in EUS guided therapy; the microwave energy allows me to precisely target and ablate difficult lesions. I believe this technology will have a positive impact on my patients, and I will continue to offer this treatment option.”

Creo chief executive Craig Gulliford added: “We are delighted to report such a positive update on our 510(k) US Food & Drug Administration cleared tissue ablation device MicroBlate Fine.”